BI and Science 37 are to collaborate by combining the latter’s remote clinical trials software platform NORA (Network Oriented Research Assistant), which uses mobile technology and telemedicine capabilities to facilitate patient participation in clinical research studies wherever they are based, and BI’s expertise in drug discovery and clinical development of novel treatments. The agreement covers use of NORA in the US only at this stage.
Chris Ceppi, Science 37’s Chief Product Officer, said: “We’ve designed NORA as a platform that provides researchers flexible options for how and where to collect evidence. Our collaboration with Boehringer Ingelheim allows us to do even more virtual trials on a larger scale - which is great news for both patients and scientists.”
“Boehringer Ingelheim collaborates with virtual clinical trials company“
Thor Voigt MD/PhD, and BI’s Chief Medical Officer, said: “Patient Centricity is a key driver for our pipeline and portfolio. Our mission is to bring novel value added therapies to patients. By leveraging a platform such as NORA, we will be able to allow patients to participate in clinical trials on their schedule and timetable. This is pivotal in ensuring patients feel they are invaluable partners in helping us to develop and deliver novel therapies worldwide.”
Noah Craft, MD, PhD, co-founder and CEO of Science 37, said: “When an industry leader in innovation such as Boehringer Ingelheim makes a commitment of this magnitude it signals a bright future for the patient-centered Metasite approach to clinical trials, and we’re glad we can help support it. We appreciate the confidence Boehringer Ingelheim has shown in Science 37 and our position as the leading technology provider for remote clinical trials.”